Search research articles
Contact Us
Filters
Showing results (91-100 of 104) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma
R S Freedman, A P Kudelka, J J Kavanagh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E Élez, I Kocáková, T Höhler, et al.
Cancer Immunology, Immunotherapy : CII
|
January 24, 1998
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
C A Savary, M L Grazziutti, B Melichar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
Clinical Pharmacology and Therapeutics
|
April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
B S Adiwijaya, J Kim, I Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U Sahin, Ö Türeci, G Manikhas, et al.
British Journal of Cancer
|
October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
T Brodowicz, I Lang, Z Kahan, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Discover Oncology
|
June 16, 2026
A rare case of angiosarcoma of the ureter
A P Goncharov, G Kharaishvili, A N Goldin, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 104) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2000
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma
R S Freedman, A P Kudelka, J J Kavanagh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2016
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T R J Evans, E Van Cutsem, M J Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
E Élez, I Kocáková, T Höhler, et al.
Cancer Immunology, Immunotherapy : CII
|
January 24, 1998
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
C A Savary, M L Grazziutti, B Melichar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
Clinical Pharmacology and Therapeutics
|
April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
B S Adiwijaya, J Kim, I Lang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U Sahin, Ö Türeci, G Manikhas, et al.
British Journal of Cancer
|
October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
T Brodowicz, I Lang, Z Kahan, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Discover Oncology
|
June 16, 2026
A rare case of angiosarcoma of the ureter
A P Goncharov, G Kharaishvili, A N Goldin, et al.
Page
of 11